Literature DB >> 29118349

Diabetes: Anti-PCSK9 antibodies - beneficial or inducers of diabetes?

Rutger Verbeek1, G Kees Hovingh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29118349     DOI： 10.1038/nrendo.2017.145

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; Philip Barter; Rafael Carmena; Prakash Deedwania; Jean-Charles Fruchart; Steven Haffner; Judith Hsia; Andrei Breazna; John LaRosa; Scott Grundy; David Waters
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

2.  Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.

Authors:  Payal Kohli; David D Waters; Rita Nemr; Benoit J Arsenault; Michael Messig; David A DeMicco; Rachel Laskey; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2015-02-03       Impact factor: 24.094

3.  Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Authors:  Dhruv S Kazi; Joanne Penko; Pamela G Coxson; Andrew E Moran; Daniel A Ollendorf; Jeffrey A Tice; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2017-08-22       Impact factor: 56.272

4.  Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Gregg C Fonarow; Anthony C Keech; Terje R Pedersen; Robert P Giugliano; Peter S Sever; Peter Lindgren; Ben van Hout; Guillermo Villa; Yi Qian; Ransi Somaratne; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

5.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Authors:  Marc S Sabatine; Lawrence A Leiter; Stephen D Wiviott; Robert P Giugliano; Prakash Deedwania; Gaetano M De Ferrari; Sabina A Murphy; Julia F Kuder; Ioanna Gouni-Berthold; Basil S Lewis; Yehuda Handelsman; Armando Lira Pineda; Narimon Honarpour; Anthony C Keech; Peter S Sever; Terje R Pedersen
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-15       Impact factor: 32.069

6.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Authors:  Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

7.  Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.

Authors:  Xin-Lin Zhang; Qing-Qing Zhu; Li Zhu; Jian-Zhou Chen; Qin-Hua Chen; Guan-Nan Li; Jun Xie; Li-Na Kang; Biao Xu
Journal:  BMC Med       Date:  2015-06-23       Impact factor: 8.775

8.  Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.

Authors:  Colin R Dormuth; Kristian B Filion; J Michael Paterson; Matthew T James; Gary F Teare; Colette B Raymond; Elham Rahme; Hala Tamim; Lorraine Lipscombe
Journal:  BMJ       Date:  2014-05-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.